Literature DB >> 14707832

Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat.

Thomas A Ciulla1, Mark H Criswell, Ronald P Danis, Jon I Williams, Michael P McLane, Kenneth J Holroyd.   

Abstract

PURPOSE: To determine if systemically administered squalamine lactate, a novel aminosterol with antineoplastic and antiangiogenic activity, inhibits the development of experimental choroidal neovascularization membranes (CNVMs) induced by laser trauma in a rat model.
METHODS: Twenty anesthetized male Brown-Norway rats received a series of 8 krypton red laser lesions per eye (647 nm, 0.05 second, 50 microm, 150 mW). One half the animals received an intraperitoneal injection of squalamine and the other one half received an injection of 5% dextrose in water, all performed in a masked fashion. Fundus photography and fluorescein angiography were performed at postlaser treatment days 14 and 28, and ocular tissues were processed for light microscopic examination following euthanasia of the rats on postlaser treatment day 28.
RESULTS: Although fundus photography and fluorescein angiography yielded no statistically significant quantitative differences between the two groups, histologic analysis of the lesion sites revealed a partial but statistically significant reduction of experimental CNVM development in the squalamine-treated population. In particular, the squalamine-treated eyes (n = 20) demonstrated lesions (n = 149) with a mean CNVM thickness +/- SD of 47 +/- 11 microm, as compared with the control eyes (n = 20) that had lesions (n = 142) with a mean CNVM thickness +/- SD of 63 +/- 14 microm (P < 0.001).
CONCLUSION: Systemically administered squalamine lactate partially reduced choroidal neovascular membrane development induced by laser trauma in this animal model. In conjunction with other existing and developing therapies, this agent may have a potential role in the treatment of human CNVM formation. Further study of squalamine lactate for treatment of neovascular eye disease is warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707832     DOI: 10.1097/00006982-200312000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

Review 1.  Age-related macular degeneration.

Authors:  Tariq Ayoub; Nishal Patel
Journal:  J R Soc Med       Date:  2009-02       Impact factor: 5.344

Review 2.  Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye.

Authors:  Abdoulaye Sene; David Chin-Yee; Rajendra S Apte
Journal:  Trends Mol Med       Date:  2014-11-01       Impact factor: 11.951

Review 3.  Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Authors:  Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  Squalamine and Its Aminosterol Derivatives: Overview of Biological Effects and Mechanisms of Action of Compounds with Multiple Therapeutic Applications.

Authors:  Nour Mammari; Elsa Salles; Audrey Beaussart; Sofiane El-Kirat-Chatel; Mihayl Varbanov
Journal:  Microorganisms       Date:  2022-06-13

5.  Doxycycline-mediated inhibition of choroidal neovascularization.

Authors:  Sonia Samtani; Juan Amaral; Maria M Campos; Robert N Fariss; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

6.  Age-related macular degeneration: current treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 7.  Vascular endothelial growth factor in eye disease.

Authors:  J S Penn; A Madan; R B Caldwell; M Bartoli; R W Caldwell; M E Hartnett
Journal:  Prog Retin Eye Res       Date:  2008-05-28       Impact factor: 21.198

8.  Marine natural products: a way to new drugs.

Authors:  V A Stonik
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

9.  Current and emerging therapies for the treatment of age-related macular degeneration.

Authors:  M Vaughn Emerson; Andreas K Lauer
Journal:  Clin Ophthalmol       Date:  2008-06

Review 10.  Marine-derived angiogenesis inhibitors for cancer therapy.

Authors:  Ying-Qing Wang; Ze-Hong Miao
Journal:  Mar Drugs       Date:  2013-03-15       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.